GLI-ME SR2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, acts by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release formulation of GLI-ME SR2 ensures a gradual release of active ingredients, promoting stable plasma drug levels and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is particularly beneficial for patients inadequately controlled on diet, exercise, and monotherapy, offering synergistic effects on blood glucose regulation. GLI-ME SR2 should be administered once daily with meals to optimize absorption and reduce gastrointestinal discomfort. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia is essential during therapy. GLI-ME SR2 Tablet provides an effective and convenient option for achieving glycemic targets in type 2 diabetes management under medical supervision.